A $12.8 million five-year renewal grant from the National Institutes of Health (NIH) will fund research that seeks to better understand the molecular mechanisms that drive chronic obstructive pulmonary disease (COPD) and other lung diseases. The research also aims to increase understanding of how cigarette smoking affects the development…
News
Twenty years after the collapse the World Trade Center, rescue workers and volunteers who assisted at the site in the two days that immediately followed face a 30% increased risk of chronic obstructive pulmonary disease (COPD), researchers report. COPD in these first responders is often preceded by a diagnosis of…
The health-related quality of life of people with chronic obstructive pulmonary disease (COPD) living in Barcelona, Spain, is negatively affected by exposure to air pollution and living farther away from green or blue water-rich spaces, a study suggests. “This study, performed for the first time on a Mediterranean population,…
Therapeutic Solutions International has filed a patent covering the therapeutic use of JadiCells — a type of mesenchymal stem cell derived from cells lining the umbilical cord — and its various combinations in treating chronic obstructive pulmonary disease (COPD). The patent application is supported by new data indicating…
Treatment with human mesenchymal stem cells (MSCs) results in a strong, but temporary, reduction in pro-inflammatory molecules involved in chronic obstructive pulmonary disease (COPD), according to data from a Phase 1 clinical trial involving nine COPD patients. Notably, molecules directly produced by MSCs were identified as potential drivers of these…
Kaleido Biosciences is teaming up with the COPD Foundation to investigate KB109, a small compound designed to modulate the gut microbiome — the community of microbes living in the intestines — as a potential treatment for chronic obstructive pulmonary disease (COPD). The decision was based on promising…
One hundred patients have been randomly assigned in Nuvaira’s pivotal AIRFLOW-3 clinical trial that will investigate the efficacy and safety of targeted lung denervation (TLD) to reduce exacerbations, or episodes of symptom worsening, of chronic obstructive pulmonary disease (COPD) in patients on optimal medical care. Because of the…
Life in the wake of the COVID-19 pandemic isn’t the only “new normal.” Wildfires in the northwestern U.S. and Canada have become regular summertime occurrences in the northern hemisphere, with more than half of U.S. states being affected by the particulate matter that blows over from the fires, according to…
Smaller particles and optimal inhalation speed of inhaler treatments — a mainstay for people with chronic obstructive pulmonary disease (COPD) — enhance their delivery to deep airway passages, a study shows. The study, “Computational evaluation of drug delivery in human respiratory tract under realistic inhalation,” was…
GoodRx, a platform for healthcare savings in the U.S., and pharmaceutical company Boehringer Ingelheim have teamed up to help lower out-of-pocket medication costs for people with chronic obstructive pulmonary disease (COPD) or type 2 diabetes. Patients will be able to enroll in sponsored copay programs to access Boehringer…
Recent Posts
- We should practice being calm for the moments when we are not
- After a missed Easter, I resolve not to let other holidays slip by unnoticed
- The value of tapping into COPD community resources
- Tozorakimab reduces COPD exacerbations in two large clinical trials
- Losing myself, finding myself: How recovery is harder with COPD